Posts by Leif W. Ellisen, MD, PhD
-
Novel Mechanism of Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer Identified by Mass General Researchers
Aditya Bardia, MD, MPH, Leif W. Ellisen, MD, PhD, and colleagues discovered that molecular alterations in both the antibody binding target and the payload target can potentially induce resistance to antibody–drug conjugates, a finding that has implications for the therapeutic sequencing of these agents.
-
Loss of REDD1 "Reprograms" Lipid Metabolism to Drive Progression of RAS-Mutant Tumors
Leif W. Ellisen, MD, PhD and Nabeel Bardeesy, PhD, of the Cancer Center, and colleagues have demonstrated that loss of the stress response gene REDD1 drives progression and poor clinical outcomes in RAS-mutant tumors—and is a potentially therapeutically actionable feature of these cancers.
Biography
Dr. Ellisen is Professor of Medicine at Harvard Medical School and Program Director for Breast Medical Oncology at the Mass General Cancer Center. He is also co-Leader of the Breast Cancer Program at the Dana-Farber/Harvard Cancer Center. He received his undergraduate degree from Harvard University, MD and PhD degrees from Stanford University, and completed residency training, oncology fellowship training, and postdoctoral research training at Brigham and Women's Hospital, the Dana-Farber Cancer Institute, and Mass General, respectively. Dr. Ellisen is widely published in the fields of cancer biology, treatment and genetics. As Director of Breast and Ovarian Cancer Genetics at Mass General, Dr. Ellisen's clinical practice is focused on cancer risk assessment, cancer prevention and early detection. Research in Dr. Ellisen's laboratory is in the vanguard of revolutionizing cancer treatment through personalized cancer therapies. Dr. Ellisen is best known for his work on triple-negative breast cancer (TNBC), one of the most aggressive forms of the disease.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
